Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PLRXthis companyPliant Therapeutics, Inc.	$0.80	-0.5×	0.41×	0×	-0.4×	-67.7%	0.0%	0.0%	0.0%	-82.4%	-71.4%	-171.9%	0.16×	0.11×	-58.65×	12×	0.0%	2	-6.55	2	B-
ARTVArtiva Biotherapeutics, Inc.	$4.21	-1.25×	0.95×	0×	-1.1×	-84.3%	0.0%	0.0%	0.0%	-76.3%	-74.9%	-75.7%	0.1×	0.19×	0×	8.61×	0.0%	1	4.66	2	C+
CLNNClene Inc.	$4.41	-2.22×	-3.29×	289.36×	-3.38×	-148.3%	78.5%	-11541.5%	-13086.5%	148.8%	-188.6%	-32.1%	-1.23×	-0.75×	-8.61×	0.83×	0.0%	2	-23.05	2	C
COYACoya Therapeutics, Inc.	$3.12	-4.57×	2.26×	12.21×	-2.37×	45.7%	99.7%	-255.0%	-267.1%	-49.3%	-46.0%	-11.1%	0×	2.21×	0×	8.5×	0.0%	3	8.76	1	D+
GUTSFractyl Health, Inc.	$0.88	-2.39×	35.68×	0×	-2.27×	52.9%	0.0%	0.0%	0.0%	-1490.3%	-89.5%	-26.9%	6.52×	0.14×	0×	4.78×	0.0%	2	-13.45	2	C+
MGNXMacroGenics, Inc.	$2.47	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
Peer median	—	-2.22×	1.83×	0.68×	-2.37×	-84.3%	71.1%	-48.7%	-49.9%	-76.3%	-74.9%	-32.1%	0.1×	0.14×	0×	5.1×	0.0%	2	-4.43	2	—